HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schwid, S. R. Articles by New York State Multiple Sclerosis Consortium*, a. t. Search for Related Content PubMed PubMed Citation Articles by Schwid, S. R. Articles by New York State Multiple Sclerosis Consortium*, a. t.

Are quantitative functional measures more sensitive to worsening MS than traditional measures?

From the Department of Neurology (Drs. Schwid and Goodman), University of Rochester Medical Center; Department of Neurology (Dr. Apatoff), New York Hospital/Cornell Medical Center, New York; Department of Neurology (Drs. Coyle and Krupp), State University of New York at Stony Brook; Department of Neurology (Drs. Jacobs, Wende, and Brownscheidle), State University of New York at Buffalo; and Department of Neurology (Dr. Miller), Maimonides Medical Center, Brooklyn, NY.

Address correspondence and reprint requests to Dr. Steven R. Schwid, 601 Elmwood Avenue, Box 605, Rochester, NY 14642; e-mail: Steven_Schwid{at}urmc.rochester.edu

The authors used data collected prospectively during a multicenter trial in 133 patients with secondary progressive MS to assess the relative sensitivity of quantitative functional tests and traditional measures, including the Expanded Disability Status Scale (EDSS) and Ambulation Index. Quantitative functional measures worsened in 69% of patients during an average of 6 months of observation, whereas the Clinical Global Impression of Change worsened in 33% and the EDSS worsened in 25% of patients. These changes should be interpreted in the context of the test–retest reliability for each measure.

This article has been cited by other articles:

				V. de Groot, H. Beckerman, B. M. J. Uitdehaag, H. C. W. de Vet, G. J. Lankhorst, C. H. Polman, and L. M. Bouter The usefulness of evaluative outcome measures in patients with multiple sclerosis Brain, October 1, 2006; 129(10): 2648 - 2659. [Abstract] [Full Text] [PDF]

				J J Kragt, F A. van der Linden, J M Nielsen, B M. Uitdehaag, and C H Polman Clinical impact of 20% worsening on Timed 25-foot Walk and 9-hole Peg Test in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 594 - 598. [Abstract] [PDF]

				S. R. Schwid and G. R. Cutter Futility studies: Spending a little to save a lot Neurology, March 14, 2006; 66(5): 626 - 627. [Full Text] [PDF]

				S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]

				J. A. Cohen, G. R. Cutter, J. S. Fischer, A. D. Goodman, F. R. Heidenreich, M. F. Kooijmans, A. W. Sandrock, R. A. Rudick, J. H. Simon, N. A. Simonian, et al. Benefit of interferon {beta}-1a on MSFC progression in secondary progressive MS Neurology, September 10, 2002; 59(5): 679 - 687. [Abstract] [Full Text] [PDF]

				S. R. Schwid, A. D. Goodman, M. P. McDermott, C. F. Bever, and S. D. Cook Quantitative functional measures in MS: What is a reliable change? Neurology, April 23, 2002; 58(8): 1294 - 1296. [Abstract] [Full Text] [PDF]